A dose determination study of NS-580 in patients with endometriosis (late phase II)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2031210685

Enrollment

372

Registered

2022-03-22

Start date

2022-04-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endometriosis

Interventions

Each participant will receive one of three oral doses (50 mg, 100 mg, 150 mg) of NS-580 or placebo twice daily over a 24-week intervention period.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: -Patients who are clinically diagnosed with endometriosis -Patients whose severity of pelvic pain caused by endometriosis meets selection criteria -Patients with regular menstrual cycle -Patients aged 20 years or older and 49 years or younger (at the time of informed consent)

Exclusion criteria

Exclusion criteria: -Patients for whom surgical treatment of organic diseases is considered to be prioritized by the investigator or subinvestigator -Patients aged 40 years or older (at the time of consent) with a longest diameter of ovarian chocolate cyst exceeding 10cm -Patients with solid image in ovarian chocolate cyst

Design outcomes

Primary

Measure	Time frame
pelvic pain	—

Contacts

Public ContactOperations Clinical

Nippon Shinyaku Co., Ltd.

zz_mail_clinical-trials@po.nippon-shinyaku.co.jp+81-120-40-8930

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026